Science
Resolves: Apr 2027 4 months left Volume: $57K

Skin cancer vaccine BLA submitted by March 31, 2027?

YES
72c
NO
28c

As of November 18, 2026, Polymarket prices “Skin cancer vaccine BLA submitted by March 31, 2027?” at 72% YES with $57K traded. No tracked wallet holds a position on this market, so there is no verdict.

Prediction markets put the probability at 72%: Skin cancer vaccine BLA submitted by March 31, 2027. Currently, markets see this as likely (72% YES).

Currently at 72%

What’s Happening

Moderna said at the Jefferies Global Healthcare Conference on Nov 18, 2026 that it plans to file a Biologics License Application for its individualized neoantigen therapy intismeran in melanoma, with potential FDA approval seen in the second half of 2027. The company has described the Marlborough facility as purpose-built for intismeran and said it is ready to support a launch. The timeline matters for the question of whether a skin cancer vaccine BLA is submitted by March 31, 2027, since the filing must precede any late-2027 approval decision. [Investing.com, Nov 18]

The filing package itself is substantial. A BLA must contain evidence supporting safety and effectiveness, along with manufacturing information, quality controls, proposed labeling and relevant nonclinical and clinical data. Analysts note that a late-2027 decision is possible only if the partners submit sufficiently early and the application is accepted promptly, given the FDA's roughly 12-month review period plus about two months for a filing decision. That review clock makes the timing of any skin cancer vaccine BLA submission by March 31, 2027 the key variable for approval in 2027. [Finance, Nov 9]

Other oncology developers are moving on similar schedules. Mirum Pharmaceuticals said it plans to submit a BLA for brelovitug in the first half of 2027 and targets a potential U.S. launch in Q4 2027 if approved, though neither milestone was reported as completed in its filing. For intismeran, the next visible steps are completion of the BLA submission and FDA acceptance; the company has not announced a submission date. The market's 72% YES pricing reflects expectations around that filing window. [Stocktitan, Nov 10]

Traded on Polymarket — $57K Volume

Trade this market on Polymarket →
OddsShift analysis: up to 5 AI models + 166 tracked wallets on every market with smart-money data. Verdict track record published on the accuracy page.

No verdict on this market

None of the 166 tracked wallets holds a position here, so the Radar makes no call — price, volume and news above are live. When a tracked wallet takes a position, this page gets a verdict.

Related Markets

Frequently Asked Questions

What are the current odds for Skin cancer vaccine BLA submitted by March 31, 2027?

As of November 2026, Polymarket prices this at 72% YES with $57K in total volume.

Where can I bet on Skin cancer vaccine BLA submitted by March 31, 2027?

This market is available on Polymarket (crypto-native, global access via USDC). OddsShift tracks prices and smart money positioning in real time.